Jyong Biotech Ltd.

Taiwanese biotech developing plant-derived drugs for urinary system diseases

What Jyong Biotech does

Jyong Biotech develops medicines made from plant-based ingredients to treat conditions of the urinary tract and prostate. Its drug candidates target an enlarged prostate and related urinary symptoms, prostate cancer, and interstitial cystitis, a chronic bladder pain condition. It is pursuing these treatments for patients in the United States, the European Union, and Asia.

How Jyong Biotech makes money

Jyong aims to earn revenue by commercializing its plant-derived drugs once they are approved, selling them in the U.S., EU, and Asian markets. As a development-stage biotech, its value depends mainly on moving its drug candidates through development toward approval.

Products & services

• Botreso (benign prostatic hyperplasia/lower urinary tract symptoms)
• PCP (prostate cancer)
• IC candidate (interstitial cystitis/bladder pain syndrome)